Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Non-Small Cell Lung Cancer: Update Bulletin [July 2014]

Product Code:
596200270
Release Date:
July 2014
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in Non-Small Cell Lung Cancer: ASCO 2014, T790M-mediated endothelial, EGFR, AstraZeneca’s AZD-9291, Clovis’ CO-1686, Novartis’ Zykadia, anaplastic lymphoma kinase, Merck Serono’s Stimuvax, Boehringer Ingelheim’s Gilotrif

Highlights from this event update bulletin

  • Physician Views Poll Results: Oncologists eager for AZD-9291 and CO-1686
  • The roles of Xalkori and Zykadia are secure for the short term, but alectinib is posed to challenge
  • Zykadia viewed as more toxic than Xalkori – KOL suggests more quality of life data needed
  • ALK inhibitors which find successful partners for combination therapy are more likely to win
  • Future positioning of ALK inhibitors dependent on availability and quality of data
  • Fate of Merck Serono’s Stimuvax is highly uncertain
  • Biomarkers key to veliparib’s and other PARP inhibitor’s success in NSCLC
  • Questions of adequate cost-benefit surround necitumumab
  • Successful head-to-head studies are key to increasing Gilotrif’s market share in NSCLC

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved